CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 11 No. 5 2
Pages: 1  2  
Next
 

Exercise Is an Important Ingredient in Ameliorating Anemia-Related Fatigue

May 1, 2002

LITTLE ROCK—For patients with cancer-related fatigue, "the first line of treatment, in my opinion, is to increase their hemoglobin levels so that they can begin an exercise program," noted William Evans, PhD. "Cancer patients suffering from primary fatigue should not be advised to increase the amount of daily rest. Rather, they should be counseled to carry out aerobic exercise," he explained. Dr. Evans serves as director, nutrition, metabolism, and exercise, and professor of geriatrics, physiology, and nutrition at the University of Arkansas for Medical Sciences in Little Rock.

An exercise physiologist by training, Dr. Evans noted that fatigue is related to reduced aerobic capacity, which can be measured by VO2max (cardiac output times the arterial/venous oxygen difference). VO2max varies enormously, with values ranging from 60 mL/kg/min. and up for professional athletes, to 50 and below for sedentary individuals. In cancer patients, VO2max levels have been measured below 20 mL/kg/min.

Benefits of rHuEPO

Dr. Evans reviewed one randomized prospective study examining the protective effects of recombinant erythropoietin(Drug information on erythropoietin) (rHuEPO) on metabolic and exercise capacity in cancer patients losing weight. The study involved 108 cancer patients, most with gastrointestinal cancers, randomized to oral indomethacin alone or with rHuEPO.

Despite being "somewhat complicated by a huge drop-out rate," the results clearly showed that hemoglobin levels and exercise capacity continued to drop in patients who did not receive rHuEPO, while patients who received it maintained relatively high hemoglobin levels of about 13 g/dL and increased their exercise capacity (see Figure 1). "The conclusion was that anemia is effectively overcome by rHuEPO in unselected cancer patients. Treatment of anemia preserved physical function, defined as exercise power and whole body metabolic efficiency," Dr. Evans said. "There is a remarkably strong relationship between change in VO2max and change in hemoglobin," he continued, "and at submaximal exercise capacities, restoring hemoglobin levels results in increased cardiac output and a change in heart rate and lactate."

Cancer fatigue is probably due not only to anemia, but also to loss of muscle mass resulting from cachexia, and severe deconditioning, Dr. Evans said. "Many cancer patients who become anemic and lose muscle mass are likely to be very inactive. Increasing their hematocrit may allow cancer patients to participate in a regular conditioning program to resolve this issue of severe deconditioning."

Reviewing the somewhat sparse literature on the subject, Dr. Evans found that cancer patients losing weight or suffering from severe fatigue had greatly reduced VO2max, equivalent only to the oxygen cost of simply walking at a normal pace of about 2½ miles per hour. "Most of the activities of daily living are well above the so-called anaerobic threshold of most cancer patients," Dr. Evans said. "That tells us two things: that their fatigue is related to their anemia and low VO2max, but also their severe deconditioning." The anaerobic threshold is the point when muscles begin producing more lactic acid(Drug information on lactic acid) than they consume and spill lactic acid into the blood, increasing respiration rate. Above the threshold it is extremely difficult to work without becoming fatigued.

Pages: 1  2  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy